Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women (ADIMOS)
Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women: a Case-control Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lille, France
- Hôpital Roger Salengro, CHU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- post-menopausal women : 50-90 years old
- Group 1 (cases) : occurence of incident major osteoporotic fracture less than 12 months
- Group 2 (controls) : no history of fragility fracture
Exclusion Criteria:
- Implants that are contraindicated for the magnetic resonance (MR) examination.
- Implants that might create a health risk or other problem during an MR exam include: 1) cardiac pacemaker or implantable defibrillator, 2) catheter that has metal components that may pose a risk of a burn injury, 3) a ferromagnetic metal clip placed to prevent bleeding from an intracranial aneurysm, 4) an implanted medication pump (such as that used to deliver insulin or a pain-relieving drug), and 5) a cochlear implant.
- body mass index [BMI] >38 kg/m2, weight >140 kg
- Disease or current use of medications known to affect bone density, including oral glucocorticoids, treatments for osteoporosis (bisphosphonates, raloxifene, calcitonin, or PTH), hormone therapy.
- Chronic kidney disease with DFG <30 ml/mn
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1 (cases)
occurence of incident major osteoporotic fracture less than 12 weeks
|
MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med.
(In%) by the DIXON sequence.
|
|
Group 2 (controls)
no history of fragility fracture
|
Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone marrow fat content at lumbar spine
Time Frame: 24 months
|
Total bone marrow fat content (percentage) at lumbar spine (L1-L4) measured with magnetic resonance imaging
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone marrow fat content at total hip
Time Frame: 24 months
|
Total bone marrow fat content (percentage) at total hip measured with magnetic resonance imaging
|
24 months
|
|
Bone mineral density at lumbar spine
Time Frame: 24 months
|
Bone mineral density (g/cm2) at lumbar spine (L1-L4) measured by DXA
|
24 months
|
|
Bone mineral density at total hip
Time Frame: 24 months
|
Bone mineral density (g/cm2) at total hip measured by DXA
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Julien Paccou, MD, PhD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016_44
- 2017-A00472-51 (Other Identifier: ID-RCB number, ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fractures, Bone
-
NCT02402868Completed
-
NCT06736457RecruitingBone Loss | Bone Fractures | Bone Defects | Bone Graft
-
NCT04207892Active, not recruiting
-
NCT04573946Active, not recruitingFractures | Bone Density | Bone Health
-
NCT03367169TerminatedLeg Injuries | Bone | Fractures | Pilon Fractures
-
NCT02338492CompletedHumerus Fracture Metastatic Bone Disease
-
NCT00766077CompletedBone Strength | Stress Fractures | Bone Geometry | Biomechanical Changes
-
NCT05528432Recruiting
Clinical Trials on Dixon Magnetic Resonance Imaging
-
NCT05047965Active, not recruiting
-
NCT00543777Completed
-
NCT02195999CompletedMuscular Dystrophy, Duchenne
-
NCT03980535CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
-
NCT02702830CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject
-
NCT00965003TerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx Cancer
-
NCT00474604Completed
-
NCT01018329Completed
-
NCT06728592RecruitingStroke | Brain Diseases | Ischemic Stroke | Stroke, Ischemic | Stroke, Acute | Stroke Hemorrhagic | Intracerebral Hemorrhage | Stroke (CVA) or TIA